Effectiveness of Immunization Products Against Medically Attended Respiratory Syncytial Virus Infection: Generic...

Area of Science:

• Public Health
• Epidemiology
• Infectious Diseases

Background:

• Respiratory syncytial virus (RSV) poses a significant public health burden, necessitating effective prevention strategies.
• Current RSV prevention approaches include monoclonal antibodies and vaccines for vulnerable populations.
• Real-world effectiveness data is crucial for evaluating these interventions.

Purpose of the Study:

• To present a generic protocol for a test-negative design study to assess RSV product effectiveness.
• To provide a flexible framework adaptable to various settings and target populations.
• To establish standardized endpoints for evaluating RSV prevention efficacy.

Main Methods:

• Utilizes a test-negative design, a robust epidemiological method for case-control studies.
• Defines severe acute respiratory infection (SARI) and acute respiratory infection (ARI) as primary endpoints.
• Applicable to both hospital-based (SARI) and general practitioner-based (ARI) studies.

Main Results:

• The protocol allows for flexible adaptation to specific study settings and target groups.
• It enables the evaluation of both monoclonal antibodies and vaccines.
• Standardized endpoints ensure comparability across different studies.

Conclusions:

• This generic protocol provides a valuable tool for monitoring the real-world effectiveness of RSV prevention products.
• It supports public health efforts by enabling rigorous evaluation of new interventions.
• The flexible design ensures broad applicability and facilitates evidence-based decision-making.